PubMed:23704121 / 1288-1571 JSONTXT

{"project":"bionlp-st-bb3-2016-training","denotations":[{"id":"T5","span":{"begin":0,"end":283},"obj":"Paragraph"}],"text":"Given the current cost and NAP1/BI/027 accounting for approximately 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin."}